Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 4Terminated 2

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 6Thoracic 4Breast 4Tumor-Agnostic 3Other hematologic neoplasm 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Small Cell Lung Carcinoma 1Recurrence 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1

Interventions

Carboplatin 463Cisplatin 379Paclitaxel 313Pemetrexed 300Docetaxel 242Erlotinib Hydrochloride 240Gemcitabine 232pembrolizumab 173Radiotherapy 172Bevacizumab 169Nivolumab 130Etoposide 106Gefitinib 95Vinorelbine 84durvalumab 71atezolizumab 68Cetuximab 65Topotecan 61Drug Therapy 57Ipilimumab 55Irinotecan 54osimertinib 53Radiosurgery 52Afatinib 51Surveys and Questionnaires 38130-nm albumin-bound paclitaxel 38Albumin-Bound Paclitaxel 37Taxes 35Cyclophosphamide 35Surgical Procedures, Operative 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × STA 9090 × Thoracic × Clear all
NCT01590160 2019-11-13

MESO-02

University College, London

Phase 1/2 Completed
27 enrolled
Other solid neoplasmThoracic

Lung Cancer - Malignant Pleural Mesothelioma

NCT01173523 2019-04-16

Study of Hsp90 Inhibitor, STA-9090 for Relapsed or Refractory Small Cell Lung Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
25 enrolled 8 charts
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT01562015 2015-05-20

CHIARA

Synta Pharmaceuticals Corp.

Phase 2 Completed
12 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01031225 2014-09-19

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Synta Pharmaceuticals Corp.

Phase 2 Completed
113 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡